17:55:22 EDT Tue 29 Apr 2025
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Medexus Pharmaceuticals Inc
Symbol MDP
Shares Issued 24,652,493
Close 2025-01-31 C$ 3.85
Market Cap C$ 94,912,098
Recent Sedar Documents

Medexus to release fiscal Q3 results Feb. 5

2025-01-31 18:21 ET - News Release

Mr. Ken d'Entremont reports

MEDEXUS SCHEDULES THIRD FISCAL QUARTER 2025 CONFERENCE CALL

Medexus Pharmaceuticals Inc. plans to host a conference call at 8 a.m. Eastern Time on Thursday, Feb. 6, 2025, to discuss Medexus's results for its third fiscal quarter ended Dec. 31, 2024. Medexus expects to file its financial statements and MD&A (management's discussion and analysis) after markets close on Feb. 5, 2025.

To participate in the call, please dial the following numbers:

  • 888-506-0062 (toll-free) for Canadian and United States callers;
  • 1-973-528-0011 for international callers;
  • Access code: 571655.

A live webcast of the call will be available on the investors section of Medexus's corporate website.

A replay of the call will be available approximately one hour following the end of the call through Thursday, Feb. 13, 2025. To access the replay, please dial the following numbers:

  • 877-481-4010 for Canadian and U.S. callers;
  • 1-919-882-2331 for international callers;
  • Conference ID: 51991.

A replay of the webcast will be available on the investors section of Medexus's corporate website until Friday, Feb. 6, 2026.

About Medexus Pharmaceuticals Inc.

Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Medexus's current focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy and dermatology.

We seek Safe Harbor.

© 2025 Canjex Publishing Ltd. All rights reserved.